Overview

A class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ : NKTR) and certain of the Company’s senior executive officers (collectively, “Defendants”), alleging violations of the federal securities laws. The Nektar lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Nektar securities between February 26, 2025, and December 15, 2025, inclusive (the “Class Period”). Investors have until May 5, 2026, to seek appointment as lead plaintiff of the Nektar class action lawsuit.

Nektar is a biopharmaceutical company focused on developing therapies for autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (“REZPEG” or “NKTR-358”), a treatment for alopecia areata, which is an autoimmune disease that causes patchy hair loss.

In February 2025, Nektar announced that it had completed its target enrollment in the REZOLVE-AA clinical trial. During the Class Period, Defendants stated that enrollment in the trial had followed applicable instructions and protocol standards, while also touting the Company’s purported drug development expertise and use of this expertise to advance its product candidates through clinical development.

The complaint alleges that Defendants made false and misleading statements and/or failed to disclose that: (i) enrollment in the REZOLVE-AA clinical trial had not followed applicable instructions and protocol standards; (ii) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial’s results; (iii) accordingly, the REZOLVE-AA trial’s overall integrity and prospects were overstated; and (iv) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The truth was revealed on December 16, 2025, when Nektar disclosed that the REZOLVE-AA trial failed to reach statistical significance, which the Company attributed to the inclusion of four patients who should not have been eligible to participate. On this news, Nektar’s stock price fell $4.14 per share, or nearly 8%, to close at $49.16 per share on December 16, 2025.

*          *          *

If you purchased or otherwise acquired Nektar securities between February 26, 2025, and December 15, 2025, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Nektar class action lawsuit is May 5, 2026.